Medicine-taking behavior: implications of suboptimal compliance in Parkinson's disease. 2005

Katherine A Grosset, and John L Reid, and Donald G Grosset
Department of Neurology, Institute of Neurological Sciences, Southern General Hospital, Glasgow, United Kingdom. D.Grosset@clinmed.gla.ac.uk

Management of Parkinson's disease (PD) depends primarily on oral medication. There are several drug classes and multiple doses and formulations, which make optimizing therapy complex. Variable drug absorption and the short half-life of most antiparkinson treatments, especially levodopa, are a main focus in understanding complications and have encouraged alternative delivery systems to limit fluctuation and dyskinesia at later stages. Comparatively little attention is paid to the way patients take their oral medication. Variable medicine-taking behavior can affect the clinician's understanding of the diagnosis and rate of progression, and further prescription of PD medication. Medicine overuse in later stage PD is well documented and causes psychiatric disturbance and increases motor complications, but evidence of undertreatment and erratic intake is emerging, which is likely to affect motor control and quality of life adversely. Methods of quantifying compliance are compared for accuracy and limitations. Understanding medicine-taking behavior is a first step in optimizing therapy and requires consideration of a patient's personal beliefs about their medicines. Although the benefits of regularizing oral medicine-taking in a practical, achievable way in PD remain untested, such an approach might prolong and smooth the benefits of oral medication and is worthy of further research.

UI MeSH Term Description Entries
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D010349 Patient Compliance Voluntary cooperation of the patient in following a prescribed regimen. Client Adherence,Client Compliance,Non-Adherent Patient,Patient Adherence,Patient Cooperation,Patient Noncompliance,Patient Non-Adherence,Patient Non-Compliance,Patient Nonadherence,Therapeutic Compliance,Treatment Compliance,Adherence, Client,Adherence, Patient,Client Compliances,Compliance, Client,Compliance, Patient,Compliance, Therapeutic,Compliance, Treatment,Cooperation, Patient,Non Adherent Patient,Non-Adherence, Patient,Non-Adherent Patients,Non-Compliance, Patient,Nonadherence, Patient,Noncompliance, Patient,Patient Non Adherence,Patient Non Compliance,Patient, Non-Adherent,Therapeutic Compliances,Treatment Compliances
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000978 Antiparkinson Agents Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists. Antiparkinson Drugs,Antiparkinsonian Agents,Antiparkinsonians,Agents, Antiparkinson,Agents, Antiparkinsonian,Drugs, Antiparkinson
D015438 Health Behavior Combination of HEALTH KNOWLEDGE, ATTITUDES, PRACTICE which underlie actions taken by individuals regarding their health. Health-Related Behavior,Behavior, Health,Behavior, Health-Related,Behaviors, Health,Behaviors, Health-Related,Health Behaviors,Health Related Behavior,Health-Related Behaviors

Related Publications

Katherine A Grosset, and John L Reid, and Donald G Grosset
November 2005, Movement disorders : official journal of the Movement Disorder Society,
Katherine A Grosset, and John L Reid, and Donald G Grosset
May 2011, Current clinical pharmacology,
Katherine A Grosset, and John L Reid, and Donald G Grosset
January 2011, Nederlands tijdschrift voor geneeskunde,
Katherine A Grosset, and John L Reid, and Donald G Grosset
January 2001, Health marketing quarterly,
Katherine A Grosset, and John L Reid, and Donald G Grosset
June 1959, Journal of personality,
Katherine A Grosset, and John L Reid, and Donald G Grosset
March 1990, Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete,
Katherine A Grosset, and John L Reid, and Donald G Grosset
June 2016, Journal of neural transmission (Vienna, Austria : 1996),
Katherine A Grosset, and John L Reid, and Donald G Grosset
March 1980, La Nouvelle presse medicale,
Katherine A Grosset, and John L Reid, and Donald G Grosset
September 2025, Sleep medicine clinics,
Katherine A Grosset, and John L Reid, and Donald G Grosset
June 2007, Biotechnology healthcare,
Copied contents to your clipboard!